Systemic Chemotherapy for Advanced or Recurrent Endometrial Cancer
For several reasons it is most common to regard endometrial cancer as a curable disease. Clinical symptoms occur early in the disease course and for the majority of patients the disease is at the time of diagnosis confined to the corpus of the uterus (FIGO-stage I). Such lesions are almost always well differentiated and a complete cure resulting from the standard treatment of surgery ± radiotherapy occurs in about 90% of the patients . Despite this evidence of success one have to take in consideration also the backside of the coin. It shows, that about one-third of all patients with this malignancy recur within 5 years from the time of diagnosis. For the Federal Republic of Germany for example this situation means that approximately 2800 patients present annually with locally advanced or recurrent disease  (Table 1). This group of patients but doesn’t suffer from a harmless disease but are possible candidates for more effective treatment approaches.
Unable to display preview. Download preview PDF.
- 1.FIGO (1985): Annual report on gynecological cancer. International Federation of Gynecology and Obstetrics. Vol. 19Google Scholar
- 2.Mailänder J. (1987): Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1986. Jahresbericht des Saarländischen Krebsregisters. In: Saarland in Zahlen (Sonderheft)Google Scholar
- 8.Seski J, Edwards C, Herson J. et al (1982): Cisplatin chemotherapy for disseminated endometrial cancer. Obstet. Gynecol. 7: 253–256Google Scholar
- 11.Thigpen JT (1980): Cisplatin in the treatment of advanced cervix and uterus cancer. Current status and new developments. Pestoyko AW, Crooke ST, Carter SK (eds) Academic Press NY pp: 411–421Google Scholar
- 14.Thigpen J. (1989): Systemic therapy with single agents for advanced or recurrent endometrial carcinoma. In: Surwit EA, Alberts DS (eds) Endometrial Cancer In: Cancer treatment and research (Series ed.: McGuire WL) Kluwer Academic Publishers Boston 1989 pp: 93–106Google Scholar
- 16.von Hoff DD, Coltman DSjr, Forseth B. (1981): Activity of mitoxantrone in a human tumor cloning system. Cancer Res. 41: 1853–1855Google Scholar
- 18.Brunner KW. (1987): Effects and side effects of chemotherapy in endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds.) Endometrial cancer Zuckschwerdt Verlag München 1987 pp: 181–189Google Scholar
- 19.Thigpen JT, Blessing J, DiSaia P. (1985): A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial cancer. Proc. Am. Soc. Clin. Oncol. 4: 115Google Scholar
- 21.Trope C, Johnson JE, Simonsen E, Christiansen H. et al.(1984): Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatinum. Am.J. Obstet. Gynecol. 149: 1025–1026Google Scholar
- 22.Malviya VK, Deppe G. (1987): Treatment of advanced recurrent endometrial cancer with cisplatin in combination chemotherapy. Poster presentation to the Society of Gynecol. Oncologists (SGO) Miami, Florida, February 3, 1987Google Scholar
- 24.Cohen CJ, Bruckner HW, Deppe G. et al.(1980): A randomized study comparing multidrug chemotherapy regimens in the treatment of advanced and recurrent endometrialcarcinoma: A Gynecologic Oncology Group Study. Obstet. Gynecol 63: 719–725Google Scholar